Company: APXIF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026189
Chunk: 14

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1A
Chunk 14
---
 warrants of OmnigenicsAI (“Company Warrants”) exercisable for Company Shares, on
substantially the same terms as the SPAC Warrants and (c) OmnigenicsAI shall enter into an Assignment, Assumption and Amendment Agreement
with the Company and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent, to amend and assume the
Company’s obligations under the existing Warrant Agreement, dated December 6, 2021, to give effect to the conversion of SPAC Warrants
to Company Warrants.

Conditions to Each Party’s Obligations 

The obligations of the parties to consummate the
Proposed Business Combination are subject to the satisfaction or waiver of customary closing conditions at or prior to the Closing, including
(a) approval by the Company’s shareholders; (b) effectiveness of the registration statement on Form F-4 relating to Company Shares
and Company Warrants to be issued in the Merger; (c) Nasdaq listing approval of the Company Shares and Company Warrants; (d) absence of
any law, rule, regulation, judgment, decree, executive order or award which is then in effect and has the effect of making the Proposed
Business Combination illegal or otherwise prohibiting consummation of the Proposed Business Combination; and (e) the Company or OmnigenicsAI
having at least $5,000,001 of net tangible assets.

5

The obligation of the Company to consummate the
Proposed Business Combination is subject to certain additional conditions at or prior to the Closing, including (a) the accuracy of certain
representations and warranties of OmnigenicsAI, MultiplAI and Merger Sub except, with respect to certain representations and warranties
required to be true and correct in all respects, where the failure of such representations and warranties to be true and correct does
not result in a Company Material Adverse Effect or MultiplAI Material Adverse Effect or is not materially adverse to Merger Sub, as applicable;
(b) OmnigenicsAI’s and Merger Sub’s performance or compliance in all material respects with all agreements and covenants required
by the Business Combination Agreement; (c) if the MultiplAI SPA has not been terminated in accordance with its terms, MultiplAI’s
performance or compliance in all material respects with all agreements and covenants required by the Business Combination Agreement and
MultiplAI SPA; (d) the consummation of the Restructuring; (e) the absence of any